Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease

Atherosclerosis

Volumn 239, Issue 1, 2015, Pages 55-60

  Mekonnen, Girum ^a   Corban, Michel T ^a   Hung, Olivia Y ^a   Eshtehardi, Parham ^a   Eapen, Danny J ^a   Al Kassem, Hatem ^a   Rasoul Arzrumly, Emad ^a   Gogas, Bill D ^a   McDaniel, Michael C ^a   Pielak, Tomasz ^b   Thorball, Christian W ^b   Sperling, Laurence ^a   Quyyumi, Arshed A ^a   Samady, Habib ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mental Health Services CPH   (Denmark)

Author keywords

Coronary microvascular function; Immune dysregulation; Inflammation; SuPAR

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UROKINASE RECEPTOR; BIOLOGICAL MARKER; PLAUR PROTEIN, HUMAN;

ADULT; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD FLOW VELOCITY; BODY MASS; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; CORONARY MICROVASCULAR FUNCTION; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONOBSTRUCTIVE CORONARY ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AGED; BLOOD; CORONARY ANGIOGRAPHY; CYTOLOGY; ENDOTHELIUM CELL; HEMODYNAMICS; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE; MICROCIRCULATION; PROSPECTIVE STUDY; RISK FACTOR;

AGED; BIOMARKERS; BLOOD FLOW VELOCITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CROSS-SECTIONAL STUDIES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODYNAMICS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTES; MALE; MICROCIRCULATION; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RISK FACTORS;

EID: 84920736165     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.025     Document Type: Article

References (47)

1. Libby P., Ridker P.M., Hansson G.K. Inflammation in atherosclerosis: from pathophysiology to practice. J.Am. Coll. Cardiol. 2009, 54:2129-2138. Leducq Transatlantic Network on A.
2. Lanza G.A., Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 2010, 121:2317-2325.
3. Dhawan S.S., Corban M.T., Nanjundappa R.A., Eshtehardi P., McDaniel M.C., Kwarteng C.A., Samady H. Coronary microvascular dysfunction is associated with higher frequency of thin-cap fibroatheroma. Atherosclerosis 2012, 223:384-388.
4. Dhawan S.S., Eshtehardi P., McDaniel M.C., Fike L.V., Jones D.P., Quyyumi A.A., Samady H. The role of plasma aminothiols in the prediction of coronary microvascular dysfunction and plaque vulnerability. Atherosclerosis 2011, 219:266-272.
5. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes D.R., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
6. Johnson B.D., Shaw L.J., Buchthal S.D., Bairey Merz C.N., Kim H.W., Scott K.N., Doyle M., Olson M.B., Pepine C.J., den Hollander J., Sharaf B., Rogers W.J., Mankad S., Forder J.R., Kelsey S.F., Pohost G.M. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109:2993-2999. National Institutes of Health-National Heart L and Blood I.
7. Gulati M., Cooper-DeHoff R.M., McClure C., Johnson B.D., Shaw L.J., Handberg E.M., Zineh I., Kelsey S.F., Arnsdorf M.F., Black H.R., Pepine C.J., Merz C.N. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch. Intern. Med. 2009, 169:843-850.
8. Thuno M., Macho B., Eugen-Olsen J. suPAR: the molecular crystal ball. Dis. Markers 2009, 27:157-172.
9. Donadello K., Scolletta S., Covajes C., Vincent J.L. suPAR as a prognostic biomarker in sepsis. BMC Med. 2012, 10:2.
10. Koch A., Voigt S., Kruschinski C., Sanson E., Duckers H., Horn A., Yagmur E., Zimmermann H., Trautwein C., Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit. Care 2011, 15:R63.
11. Wittenhagen P., Kronborg G., Weis N., Nielsen H., Obel N., Pedersen S.S., Eugen-Olsen J. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin. Microbiol. Infect. 2004, 10:409-415.
12. Ostrowski S.R., Ullum H., Goka B.Q., Hoyer-Hansen G., Obeng-Adjei G., Pedersen B.K., Akanmori B.D., Kurtzhals J.A. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J.Infect. Dis. 2005, 191:1331-1341.
13. Slot O., Brunner N., Locht H., Oxholm P., Stephens R.W. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann. rheumatic Dis. 1999, 58:488-492.
14. Chu S.C., Yang S.F., Lue K.H., Hsieh Y.S., Hsiao T.Y., Lu K.H. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee. J.rheumatology 2006, 33:311-317.
15. Toldi G., Beko G., Kadar G., Macsai E., Kovacs L., Vasarhelyi B., Balog A. Soluble urokinase plasminogen activator receptor (suPAR) in the assessment of inflammatory activity of rheumatoid arthritis patients in remission. Clin. Chem. laboratory Med.: CCLM/FESCC 2013, 51:327-332.
16. Kienast J., Padro T., Steins M., Li C.X., Schmid K.W., Hammel D., Scheld H.H., van de Loo J.C. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb. Haemost. 1998, 79:579-586.
17. Lyngbaek S., Andersson C., Marott J.L., Moller D.V., Christiansen M., Iversen K.K., Clemmensen P., Eugen-Olsen J., Hansen P.R., Jeppesen J.L. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. Clin. Chem. 2013, 59:1621-1629.
18. Lyngbaek S., Marott J.L., Moller D.V., Christiansen M., Iversen K.K., Clemmensen P.M., Eugen-Olsen J., Jeppesen J.L., Hansen P.R. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. Am. J. Cardiol. 2012, 110:1756-1763.
19. Persson M., Ostling G., Smith G., Hamrefors V., Melander O., Hedblad B., Engstrom G. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke; a J. Cereb. Circulation 2014, 45:18-23.
20. Eugen-Olsen J., Andersen O., Linneberg A., Ladelund S., Hansen T.W., Langkilde A., Petersen J., Pielak T., Moller L.N., Jeppesen J., Lyngbaek S., Fenger M., Olsen M.H., Hildebrandt P.R., Borch-Johnsen K., Jorgensen T., Haugaard S.B. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J.Intern Med. 2010, 268:296-308.
21. Sehestedt T., Lyngbaek S., Eugen-Olsen J., Jeppesen J., Andersen O., Hansen T.W., Linneberg A., Jorgensen T., Haugaard S.B., Olsen M.H. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. Atherosclerosis 2011, 216:237-243.
22. Persson M., Engstrom G., Bjorkbacka H., Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study. Atherosclerosis 2012, 220:502-505.
23. Eapen D.J., Manocha P., Ghasemzedeh N., Patel R.S., Al Kassem H., Hammadah M., Veledar E., Le N., Pielak T., Thorball C.W., Velegraki A., Kremastinos D., Leraki S., Sperling L., Quyyumi A.A. Soluble Urokinase Plasminogen Activator Receptor (suPAR) level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J.Am. Heart Assoc. 2014, Ahead of publication.
24. Lyngbaek S., Marott J.L., Sehestedt T., Hansen T.W., Olsen M.H., Andersen O., Linneberg A., Haugaard S.B., Eugen-Olsen J., Hansen P.R., Jeppesen J. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. Int. J. Cardiol. 2013, 167:2904-2911.
25. Tsimikas S., Willerson J.T., Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J.Am. Coll. Cardiol. 2006, 47:C19-C31.
26. Cozen A.E., Moriwaki H., Kremen M., DeYoung M.B., Dichek H.L., Slezicki K.I., Young S.G., Veniant M., Dichek D.A. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation 2004, 109:2129-2135.
27. Tona F., Serra R., Di Ascenzo L., Osto E., Scarda A., Fabris R., Montisci R., Famoso G., Tellatin S., Foletto M., Giovagnoni A., Iliceto S., Vettor R. Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease. Nutr. Metabolism, Cardiovasc. Dis.: NMCD 2014, 24:447-453.
28. Vaccarino V., Khan D., Votaw J., Faber T., Veledar E., Jones D.P., Goldberg J., Raggi P., Quyyumi A.A., Bremner J.D. Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins. J.Am. Coll. Cardiol. 2011, 57:1271-1279.
29. Samady H., Eshtehardi P., McDaniel M.C., Suo J., Dhawan S.S., Maynard C., Timmins L.H., Quyyumi A.A., Giddens D.P. Coronary artery wall shear stress is associated with progression and transformation of atherosclerotic plaque and arterial remodeling in patients with coronary artery disease. Circulation 2011, 124:779-788.
30. Eshtehardi P., Luke J., McDaniel M.C., Samady H. Intravascular imaging tools in the cardiac catheterization laboratory: comprehensive assessment of anatomy and physiology. J.Cardiovasc. Transl. Res. 2011, 4:393-403.
31. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell. Biol. 2010, 11:23-36.
32. Edsfeldt A., Nitulescu M., Grufman H., Gronberg C., Persson A., Nilsson M., Persson M., Bjorkbacka H., Goncalves I. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke; a J. Cereb. circulation 2012, 43:3305-3312.
33. Svensson P.A., Olson F.J., Hagg D.A., Ryndel M., Wiklund O., Karlstrom L., Hulthe J., Carlsson L.M., Fagerberg B. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. Int. J. Mol. Med. 2008, 22:459-464.
34. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 2006, 6:508-519.
35. Mach F., Schonbeck U., Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis?. Atherosclerosis 1998, 137(Suppl.l):S89-S95.
36. Jonasson L., Holm J., Skalli O., Bondjers G., Hansson G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arterioscler. (Dallas, Tex) 1986, 6:131-138.
37. Salonen J.T., Yla-Herttuala S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., Witztum J.L. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
38. Fredrikson G.N., Hedblad B., Berglund G., Alm R., Ares M., Cercek B., Chyu K.Y., Shah P.K., Nilsson J. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:872-878.
39. Nakanishi K., Fukuda S., Shimada K., Miyazaki C., Otsuka K., Maeda K., Miyahana R., Kawarabayashi T., Watanabe H., Yoshikawa J., Yoshiyama M. Impaired coronary flow reserve as a marker of microvascular dysfunction to predict long-term cardiovascular outcomes, acute coronary syndrome and the development of heart failure. Circulation J.:Official J. Jpn. Circulation Soc. 2012, 76:1958-1964.
40. Camici P.G., Crea F. Coronary microvascular dysfunction. N.Engl. J. Med. 2007, 356:830-840.
41. Gould K.L., Lipscomb K., Hamilton G.W. Physiologic basis for assessing critical coronary stenosis. Am. J. Cardiol. 1974, 33:87-94.
42. Kern M.J., Lerman A., Bech J.W., De Bruyne B., Eeckhout E., Fearon W.F., Higano S.T., Lim M.J., Meuwissen M., Piek J.J., Pijls N.H., Siebes M., Spaan J.A. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. Circulation 2006, 114:1321-1341. American Heart Association Committee on D and Interventional Cardiac Catheterization CoCC.
43. Tsukamoto T., Morita K., Naya M., Katoh C., Inubushi M., Kuge Y., Tsutsui H., Tamaki N. Myocardial flow reserve is influenced by both coronary artery stenosis severity and coronary risk factors in patients with suspected coronary artery disease. Eur. J. Nucl. Med. Mol. imaging 2006, 33:1150-1156.
44. Eapen D.J., Manocha P., Patel R.S., Hammadah M., Veledar E., Wassel C., Nanjundappa R.A., Sikora S., Malayter D., Wilson P.W., Sperling L., Quyyumi A.A., Epstein S.E. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J.Am. Coll. Cardiol. 2013, 62:329-337.
45. Ciuffetti G., Lombardini R., Pirro M., Lupattelli G., Mannarino E. Clopidogrel: hemorheological effects in subjects with subclinical atherosclerosis. Clin. Hemorheol. Microcirc. 2001, 25:31-39.
46. Bugiardini R., Borghi A., Biagetti L., Puddu P. Comparison of verapamil versus propranolol therapy in syndrome X. Am. J. Cardiol. 1989, 63:286-290.
47. Lanza G.A., Colonna G., Pasceri V., Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in syndrome X. Am. J. Cardiol. 1999, 84:854-856. A8.